AttardLab Profile picture
Understanding treatment resistance in prostate cancer @uclcancer. Tweets by Gert & team.

Sep 19, 2021, 6 tweets

Excited to share the latests results from the STAMPEDE clinical trial: abiraterone plus prednisolone with or without enza added to ADT compared to ADT alone in high risk nonmetastatic #prostatecancer patients #ESMO21

None of this would be possible without all the patients, supported by their family/friends, all the site staff involved in the trial, our pharma partners @AstellasEurope @JanssenUK, our funders @The_MRC @CR_UK, and the efforts of the whole team @MRCCTU #ESMO21

More details on the study design enabling this comaprison, including our amendment to the reporting plan reader.elsevier.com/reader/sd/pii/… #ESMO21

2 years of abiraterone+prednisolone based therapy significantly improves metastasis-free survival and overall survival of high risk nonmetastatic prostate cancer patients and should be considered a new standard of care #ESMO21

Looking forward to the discussion session #ESMO21

Share this Scrolly Tale with your friends.

A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.

Keep scrolling